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Scope: The physiological relevance of contemporary cell culture studies is often perplexing,
given the use of unmetabolized phytochemicals at supraphysiological concentrations. We in-
vestigated the activity of physiologically relevant anthocyanin metabolite signatures, derived
from a previous pharmacokinetics study of 500 mg 13C5-cyanidin-3-glucoside in eight healthy
participants, on soluble vascular adhesion molecule-1 (VCAM-1) and interleukin-6 (IL-6) in
human endothelial cells.
Methods and results: Signatures of peak metabolites (previously identified at 1, 6, and 24 h
post-bolus) were reproduced using pure standards and effects were investigated across concen-
trations ten-fold lower and higher than observed mean (<5 M) serum levels. Tumor necrosis
factor- (TNF-)-stimulated VCAM-1 was reduced in response to all treatments, with maximal
effects observed for the 6 and 24 h profiles. Profiles tested at ten-fold below mean serum con-
centrations (0.19–0.44 M) remained active. IL-6 was reduced in response to 1, 6, and 24 h
profiles, with maximal effects observed for 6 h and 24 h profiles at concentrations above 2 M.
Protein responses were reflected by reductions in VCAM-1 and IL-6mRNA, however there was
no effect on phosphorylated NFB-p65 expression.
Conclusion: Signatures of anthocyanin metabolites following dietary consumption reduce
VCAM-1 and IL-6 production, providing evidence of physiologically relevant biological activity.
Keywords:
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1 Introduction
The consumption of anthocyanins has been linked to a
reduced risk of cardiovascular disease [1, 2], though their
mechanisms of action are not fully understood. Traditionally,
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in vitro studies have explored the activity of parent antho-
cyanins mechanistically, however their low plasma concen-
trations and rapid clearance kinetics suggests they are not the
bioactive forms responsible for in vivo activity. It is therefore
probable that anthocyanin bioactivity in vivo results from the
lesser studied, though more bioavailable, phenolic metabo-
lites, and we have recently demonstrated they are more active
on inflammatory biomarkers than their precursor structures
[3–5].
The understanding of anthocyanin metabolism is rela-
tively contemporary, though it is commonly accepted that
their degradation is a result of their chemical instability and
the impact of bacterial catabolism, resulting in a number
C© 2017 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
1700053 (2 of 10) E. F. Warner et al. Mol. Nutr. Food Res. 00, 0, 2017, 1700053
0
500
1000
1500
2000
2500
4842363024181260
Co
nc
en
tra
tio
n 
(nM
)
Time (h)
Cyanidin-3-glucoside Hippuric acid
Ferulic acid Phloroglucinaldehyde
4-Hydroxybenzoic aldehyde Benzoic acid-4-glucuronide
Protocatechuic acid Protocatechuic acid-3/4-glucuronide
Protocatechuic acid-3/4-sulfate Vanillic acid
Isovanillic acid Vanillic acid-4-glucuronide
Isovanillic acid-3-glucuronide Vanillic acid-4-sulfate/Isovanillic acid-3-sulfate
Figure 1. Serum pharmacokinetic signatures of C3G and its metabolites in humans after the consumption of 500 mg 13C5-C3G in eight
healthy male participants. Data represent mean concentration of specified metabolites from eight participants. Peak signatures (at 1,
6, and 24 h) are indicated by the dashed-line boxes. “/” indicates isomers quantified together. Common name (chemical name): 4-
hydroxybenzyldehyde (4-hydroxybenzoicaldehyde); Benzoic acid-4-glucuronide (benzoic acid-4-O-glucuronide); Cyanidin-3-glucoside (2-
(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromeniumyl--D-glucopyranoside); Ferulic acid (4-hydroxy-3-methoxycinnamic acid); Hippuric
acid (N-benzoylglycine); Isovanillic acid (3-hydroxy-4-methoxybenzoic acid); Isovanillic acid-3-glucuronide (4-methoxybenzoic acid-3-O-
glucuronide); Isovanillic acid-3-sulfate (4-methoxybenzoic acid-3-sulfate); Phloroglucinaldehyde (2,4,6-trihydroxybenzaldehyde); Protocat-
echuic acid (3,4-dihydroxybenzoic acid); Protocatechuic acid-3-sulfate (4-hydroxybenzoic acid-3-sulfate); Protocatechuic acid-4-glucuronide
(3-hydroxybenzoic acid-4-O-glucuronide); Protocatechuic acid-4-sulfate (3-hydroxybenzoic acid-4-sulfate); Vanillic acid (3-methoxy-4-
hydroxybenzoic acid); Vanillic acid-4-glucuronide (3-methoxybenzoic acid-4-O-glucuronide); Vanillic acid-4-sulfate (3-methoxybenzoic acid-
4-sulfate). Adapted from de Ferrars et al. [11].
of circulating phenolic metabolites [6, 7]. As anthocyanin
metabolites do not circulate in isolation following ingestion,
but exist as complex mixtures or profiles of metabolites at
various concentrations [8–10], it is important that this is also
reflected in the design of experiments exploring the bioactiv-
ity of anthocyanins.
The metabolism of a common dietary anthocyanin,
cyanidin-3-glucoside (C3G), was recently investigated and 29
metabolites were identified following the consumption of
500 mg 13C-labelled cyanidin-3-glucoside (C3G) [8, 11].
Briefly, eight healthy male participants were fed a single
500mg oral bolus dose of isotopically labeled C3G (13C5-C3G)
following a 7-day washout period (avoiding anthocyanin-rich
foods), where bloodwas collected at baseline, 0.5, 1, 2, 4, 6, 24,
and 48 h. Three distinct peak serum metabolite profiles (or
signatures) were observed post consumption at 1, 6, and 24 h
(Fig. 1). Similar groupings of metabolites sharing Cmax and
producing distinct biosignatures or peaks of metabolites dur-
ing clearance have also been observed following consumption
of cocoa flavan-3-ols [12] and citrus flavanones [13], suggest-
ing this is a common response in the clearance kinetics of
flavonoid metabolites. Given that these phenolics circulate
at higher concentrations and for longer duration relative to
their precursor structures, there is scope to investigate the
collective activity of blood profiles of phenolic metabolites on
inflammatory processes.
Anthocyanin metabolites have been shown to inhibit the
expression of a number of inflammatory biomarkers, such as
those involved in vascular adhesion and chemotaxis, includ-
ing soluble vascular cellular adhesion molecule-1 (VCAM-1)
and interleukin-6 (IL-6) [14, 15], both of which are markers
of cardiovascular disease risk and mortality [16, 17] and log-
ical targets for exploring the potential mechanisms of ac-
tion of anthocyanin metabolites. The aims of the present
study were therefore: investigate the effects of unique C3G
metabolite signatures, observed to peak in vivo at 1, 6, and
24 h post consumption, on VCAM-1 and IL-6 protein se-
cretion by two cell types, human umbilical vein endothe-
lial cells (HUVEC) and human coronary artery endothelial
cells (HCAECs); investigate the effects of metabolite signa-
tures across a range of concentrations, reflecting levels ten-
fold lower (<0.5 M) and ten-fold higher (<50 M) than
mean concentrations (<5 M) observed previously [8, 11];
finally, identify mechanistic effects on VCAM-1 and IL-6
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Table 1. Serum profile constituents and concentrations
Analyte Final profile concentration (nM)
1 h profile 6 h profile 24 h profile
4-Hydroxybenzyldehyde 1 10 100 1 10 100 1 10 100
Benzoic acid-4-glucuronide 1 10 100 4 40 400 4 40 400
Cyanidin-3-glucoside 5 50 500 0 0 0 0 0 0
Ferulic acid 29 290 2900 21 210 2100 59 590 5900
Hippuric acid 7 70 700 23 230 2300 194 1940 19 400
Isovanillic acid 12 120 1200 0 0 0 0 0 0
Isovanillic acid-3-glucuronide 1 10 100 2 20 200 0 0 0
Isovanillic acid-3-sulfate 0 0 0 0 0 0 17 170 1700
Phloroglucinaldehyde 3 30 300 55 550 5500 5 50 500
Protocatechuic acid 4 40 400 8 80 800 1 10 100
Protocatechuic acid-3-sulfate 7 70 700 2 20 200 2 20 200
Protocatechuic acid-4-glucuronide 2 20 200 3 30 300 0 0 0
Protocatechuic acid-4-sulfate 7 70 700 2 20 200 2 20 200
Vanillic acid 110 1100 11 000 80 800 8000 136 1360 13 600
Vanillic acid-O-4-glucuronide 1 10 100 2 20 200 0 0 0
Vanillic acid-4-sulfate 0 0 0 0 0 0 17 170 1700
Total 190 1900 19 000 203 2030 20 300 438 4380 43 800
Common name (chemical name): 4-hydroxybenzyldehyde (4-hydroxybenzoicaldehyde); Benzoic acid-4-glucuronide (benzoic acid-
4-O-glucuronide); Cyanidin-3-glucoside (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromeniumyl--D-glucopyranoside); Ferulic acid (4-
hydroxy-3-methoxycinnamic acid); Hippuric acid (N-benzoylglycine); Isovanillic acid (3-hydroxy-4-methoxybenzoic acid); Isovanillic acid-3-
glucuronide (4-methoxybenzoic acid-3-O-glucuronide); Isovanillic acid-3-sulfate (4-methoxybenzoic acid-3-sulfate); Phloroglucinaldehyde
(2,4,6-trihydroxybenzaldehyde); Protocatechuic acid (3,4-dihydroxybenzoic acid); Protocatechuic acid-3-sulfate (4-hydroxybenzoic acid-3-
sulfate); Protocatechuic acid-4-glucuronide (3-hydroxybenzoic acid-4-O-glucuronide); Protocatechuic acid-4-sulfate (3-hydroxybenzoic acid-
4-sulfate); Vanillic acid (3-methoxy-4-hydroxybenzoic acid); Vanillic acid-4-glucuronide (3-methoxybenzoic acid-4-O-glucuronide); Vanillic
acid-4-sulfate (3-methoxybenzoic acid-4-sulfate).
mRNAby targeting a key inflammatory transcriptional target,
NFB.
2 Methods
2.1 Materials
Early passage human umbilical vein endothelial cells
(HUVECs) (cryopreserved, pooled donors, passage 2), large
vessel endothelial growth medium (containing 2% fetal calf
serum, human epidermal growth factor, human fibroblast
growth factor, 25 g/mL gentamycin, 50 ng/mL ampho-
tericin, hydrocortisone and heparin) and trypsin passage
pack were purchased from Caltag Medsystems (Bucking-
ham, UK). Early passage (passage 2) human coronary artery
endothelial cells (HCAECs) (cryopreserved, single donors),
endothelial cell mediumMV (containing 5% fetal calf serum,
endothelial cell growth supplement, recombinant human
epidermal growth factor, heparin, and hydrocortisone)
and Detach Kit were purchased from PromoCell GmbH
(Heidelberg, Germany). The conjugated metabolites, as
listed in Table 1, were synthesized at the University of St.
Andrews (UK) [18]. Human-derived fibronectin, TNF-, and
all flavonoids and unconjugated phenolic acids (Table 1)
were obtained from Sigma Aldrich (Dorset, UK), with the
exception of cyanidin-3-glucoside (Extrasynthase, France).
2.2 Treatment metabolite profiles
Stock solutions for cell culture experiments were prepared
in 100% DMSO at 200 mM and stored at -80C with the
exception of cyanidin-3-glucoside, which was prepared at
40 mM, and the sulfate- conjugated phenolic acids, which
were prepared at 25 mM in 50% DMSO (50% PBS) to
maintain stability whilst reducing final DMSO concentra-
tions in working solutions. Working solutions of 1 mM
were prepared in supplemented media before being di-
luted to their working concentrations (Table 1) and stored
at 4C until experimental commencement (with the ex-
ception of cyanidin-3-glucoside, which was added imme-
diately prior to the final dilutions to maintain stability).
Solutions were subsequently diluted in supplemented me-
dia as required (Table 1) immediately prior to experiment
commencement.
2.3 Cell culture
HUVECs andHCAECswere routinely cultured in fibronectin
coated T75 flasks (0.25 g/cm2), using large vessel en-
dothelial growth medium and endothelial cell medium MV,
respectively, at 37C and 5% CO2. Cells were sub-cultured
using a trypsin passage pack or Detach Kit, according to the
manufacturer’s instructions. HUVECs were used at passage
C© 2017 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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4 and HCAECs were used between passages 3 and 6. All
cells were incubated in supplemented media for 24 h at 37C,
5% CO2, in a humidified atmosphere, prior to experiment
commencement.
2.4 VCAM-1 and IL-6 protein expression
HUVEC or HCAEC were seeded at 80 000 cells/well in fi-
bronectin coated 24-well plates. Cells were treated for 30 min
with peak metabolite profiles identified previously at 1, 6,
24 h post consumption (Table 1) or 0.01% DMSO (vehi-
cle control) prior to the addition of 10 ng/mL (HUVEC) or
0.1 ng/mL (HCAEC) TNF- (determined as providing max-
imal induction while maintaining physiologically relevant
concentrations following time- and concentration-response
experiments), and incubated for 24 h at 37C, 5% CO2, in a
humidified atmosphere. Supernatants were collected on ice,
centrifuged at 2000 ×g for 10 min at 4C, and stored at -80C
prior to ELISA. Samples were thawed at room temperature
and vortexed for 3 × 5 s immediately prior to analysis. Super-
natants were diluted 1:1 in Reagent Diluent (R&D Systems)
and protein expression of soluble VCAM-1 (sVCAM-1; hereby
referred to as VCAM-1) and IL-6 were determined by com-
mercially available DuoSet enzyme-linked immunosorbent
assay (ELISA) (R&D Systems), according to the manufac-
turer’s instructions. Absorbance values for all ELISA plates
were recorded using an OMEGA plate reader from BMG
LABTECH (Bucks, UK).
2.5 VCAM-1 and IL-6 mRNA expression
HCAEC were seeded at 200 000 cells/well in fibronectin
coated 6-well plates. Cells were pre-treated for 30 min with
the highest working concentrations of the metabolite profiles
(19, 20, 44 M, reflecting serum concentrations at 1, 6,
24 h respectively) of each serum profile or 0.01% DMSO
(vehicle control) prior to the addition of 0.1 ng/mL TNF-,
and incubated for 4 h at 37C, 5% CO2, in a humidified
atmosphere. Cell culture supernatants were removed
and cells washed 3× with PBS. Total RNA was extracted
from HUVECs and reverse transcribed to cDNA using
conditions previously described [3]. Real-time quantitative
PCR (RT-qPCR) was carried out using 25 ng cDNA with
the addition of VCAM-1 primers (forward primer, 5’-
CAGGCTAAGTTACATATTGATGACAT-3’; reverse primer,
5’-GAGGAAGGGCTGACCAAGAC-3’), or IL-6 primers
(forward primer, 5’-GCAGAAAACAACCTGAACCTT;
reverse primer, 3’-ACCTCAAACTCCAAAAGACCA-5’) and
real-time PCR Precision master mix with SYBR green
(Primer Design, UK). RT-qPCR was carried out using the
ABI7500 (Applied Biosystems, UK) system, using cycle
methods previously described [3]. Relative changes in gene
expression from the TNF- control were quantified using
the comparative Ct method [19]. The difference between
recorded Ct values for treatment and positive control samples
were calculated in the first instance for all genes. geNORM
analysis was carried out using qbasePLUS software (version
2.3; Biogazelle, Belgium) to determine stable reference genes
(VIPAS39 and PRDM4), the geometric mean of which were
used to normalize the data in subsequent experiments.
2.6 Phospho-NFB p65 expression
HCAEC were seeded at 200 000 cells/well in fibronectin
coated 6-well plates. Cells were pre-treated for 30 min with
the highest working concentrations of each serum profile
(19, 20, 44 M, reflecting 1, 6, and 24 h serum concentra-
tions respectively) or 0.01% DMSO (vehicle control) prior to
the addition of 10 ng/mL TNF-, and incubated for 15 min
at 37C, 5% CO2, in a humidified atmosphere. Cells were
washed 3× with PBS and lysed with NP-40 lysis buffer; to-
tal protein concentrations were determined by BCA assay,
and proteins were separated and probed by SDS-PAGE and
Western blotting, respectively, as described previously by this
group [20]. Primary antibody solution contained 0.1% PBS
with 20% T20 Blocking Buffer (Thermoscientific, UK), with
rabbit polyclonal anti-NFB p65 (Ser536) antibody (ab28856;
Abcam, UK; 1:2000 dilution) and chicken polyclonal anti-
GAPDH (AB2302; Millipore, UK; 1:15 000 dilution) and sec-
ondary antibody solutions contained 0.1% PBS with 20%
T20 Blocking Buffer and 0.1% SDS, with goat anti-rabbit
(IRdye 800CW; Li-Cor, UK; 1:15 000 dilution) and donkey-
anti-chicken (IRdye 680LT; Li-Cor, UK; 1:15 000 dilution).
Membranes were imaged and quantified by densitometry at
700 nm and 800 nm using Odyssey Infrared Imaging System
and Odyssey Infrared Imaging System Application Software,
respectively (Li-Cor; version 3.0.21).
2.7 Data analysis
VCAM-1 and IL-6 protein (pg/mL) or mRNA (fold change)
were recorded as the mean of two technical duplicates, and
reported relative to the TNF- positive control (containing
TNF- without DMSO) as the mean of three independent ex-
periments. Phospho-NFB p65 expression (infrared density)
data were normalized to GAPDH reference gene and data
were presented graphically as a fold change of vehicle con-
trol (DMSO). Treatment effects were established by one-way
analysis of variance (ANOVA) with post-hoc least significant
difference (LSD) conducted using SPSS for Windows (ver-
sion 22.0; IBM, New York, USA). Untreated controls were
not included in theANOVA for treatment effect but presented
graphically, where Students t-test established difference rel-
ative to vehicle control (DMSO). All data represent the mean
± SD of three biological replicates (n = 3).
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Figure 2. Effect of peakmetabo-
lite signatures on TNF- stim-
ulated VCAM-1 secretion by A)
HUVEC, B) HCAEC. Cells were
treated with three concentra-
tions of three serum metabolite
profiles (representing ten-fold
lower and ten-fold higher con-
centrations than the mean con-
centrations observed by Czank
et al. [8]; Table 1) prior to the
addition of 10 or 0.1 ng/mL
TNF- for 24 h. Data were
normalized to a TNF- con-
trol (no DMSO) and columns
represent the mean ± SD,
n = 3 biological replicates. La-
beledmeanswithout a common
letter differ, p  0.05 (ANOVA
with post hoc LSD). *Different
from DMSO, p  0.05 (t-test).
Abbreviations: HUVEC, human
umbilical vein endothelial cells;
TNF-, tumor necrosis factor-;
VCAM-1, soluble vascular adhe-
sion molecule-1.
3 Results
3.1 Effect of peak cyanidin-3-glucoside metabolite
signatures on VCAM-1 protein expression
The effects of signatures of cyanidin-3-glucoside metabolites
(Fig. 1) on TNF- stimulated VCAM-1 secretion was explored
at the mean concentrations observed clinically, as well as
concentrations ten-fold lower and ten-fold higher (Table 1),
in HUVEC and validated in HCAEC. No treatments were cy-
totoxic at any tested concentration as established utilizing the
WST-1 cytotoxicity assay (Roche, United Kingdom). HUVEC-
secreted VCAM-1 (Fig. 2A) was reduced relative to the vehicle
control in response to all treatments at all tested concen-
trations, with the maximal effects observed for 6 and 24 h
metabolite signatures (−65.12 ± 0.37% and −66.24 ± 2.88,
respectively; p  0.001) at cumulative concentrations of 20
and 44 M (respectively). The activity expressed in HCAEC
was slightly less than that of the HUVEC, however simi-
larly, inhibition of HCAEC-secreted VCAM-1 (Fig. 2B) was
greatest for treatments reflecting the 6 and 24 h metabo-
lite signatures (−30.07 ± 11.41% and −27.84 ± 3.09%, re-
spectively; p  0.001). For both cell lines, even the profiles
tested at concentrations 10-fold below the mean serum levels
C© 2017 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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reported (0.19, 0.20, 0.44 M reflecting serum profiles at 1,
6, and 24 h, respectively) significantly reduced VCAM-1 se-
cretion (p  0.05).
3.2 Effect of peak cyanidin-3-glucoside metabolite
signatures on IL-6 protein expression
The effects of cyanidin-3-glucoside metabolite signatures
(Fig. 1) on TNF- stimulated IL-6 secretion was explored at
the mean concentration observed clinically (Table 1), as well
as ten-fold lower and ten-fold higher concentrations in HU-
VECand validated inHCAEC.HUVEC-secreted IL-6 (Fig. 3A)
was reduced relative to the vehicle control in response to all
treatments, with the exception of the concentrations tested
10-fold below the mean serum levels (0.19, 0.20, 0.44 M re-
flecting serum concentrations at 1, 6, and 24 h, respectively).
Maximal effects on IL-6 were observed in response to the
three metabolite signatures (1, 6, and 24 h) at cumulative
concentrations of 2, 20, and 44 M, respectively (−36.63 ±
3.73%, −31.26 ± 8.06%, −35.56 ± 0.70%; p  0.001). Activ-
ity was not reduced in HCAEC in response to any treatment
(p> 0.05; Fig. 3B).Maximal concentrations of eachmetabolite
signature (19, 20, 44 M), reflecting serum concentrations at
1, 6, and 24 h (respectively) were taken forward to confirm
their effect on VCAM-1 and IL-6 mRNA in HCAEC.
3.3 Effect of peak cyanidin-3-glucoside metabolite
profiles on VCAM-1 and IL-6 mRNA expression
Peak metabolite signatures were used to determine whether
TNF- stimulated VCAM-1 and IL-6 protein secretion was re-
flected by mRNA expression in HCAEC (Fig. 4). Here TNF-
stimulated VCAM-1 mRNA expression was reduced by 0.55
± 0.25 fold, 0.49 ± 0.13 fold, and 0.36 ± 0.21 fold in response
to 19, 20, 44 M concentrations as observed clinically at 1,
6, and 24 h (respectively), compared to the vehicle control
(Fig. 4A). TNF- stimulated IL-6 mRNA expression was re-
duced by 0.93 ± 0.10 fold, 1.18 ± 0.30 fold, and 1.01 ± 0.54
fold in response to 19, 20, and 44 M treatment profiles as
observed clinically at 1, 6, and 24 h, respectively (p  0.05;
Fig. 4B).
3.4 Effect of peak cyanidin-3-glucoside metabolite
signatures on phosphorylated NFB p65
expression
Peak metabolite signatures were further explored for their
effect on TNF- stimulated NFB transcription factor p65 in
HCAEC (Fig. 5), where there was no apparent activity beyond
that of the vehicle control (p > 0.05).
4 Discussion
The present study is the first to explore the activity of
physiologically relevant signatures of anthocyanin metabo-
lites. Here we utilized three unique treatments based on
peak concentrations observed in serum post consumption
(Fig. 1) [8, 11], with the aim of elucidating in vivo activity.
Peak signatures of metabolites (Table 1) displayed significant
inhibitory effects on VCAM-1 protein secretion (Fig. 2) at
concentrations observed in vivo [11], suggesting physiologi-
cally achievable bioactivity. The greatest inhibition of VCAM-
1 was observed in response to the 24 h metabolite signa-
ture, suggesting metabolites of lower intestinal microbial ori-
gin are responsible for fasting or chronic anti-inflammatory
effects.
Peak metabolite signatures appeared to have biological
activity, despite the extremely low concentrations of their
individual constitutes. Here responses were often greater
then activities previously reported by our group for the same
metabolites in isolation or in mixtures at equal molar con-
centrations [4, 5]. Previous studies have explored this con-
cept of physiologically relevant concentrations of metabolite
profiles by applying extracted serum/plasma to cell culture
models. For example, Koga et al. found serum containing
metabolites of (+)-catechin significantly reduced U937 adhe-
sion to human aortic endothelial cells (HAEC) relative to the
pure metabolites in isolation [21]. Other studies have used
both extracted animal and human plasma in a similar man-
ner [22–24], however the limitation of this study design is
that plasma contains many bioactive constituents other than
flavonoid metabolites, making it difficult to compare treat-
ments to controls and eliminate confounders stemming from
varying endogenous analytes. There is scope to validate the
present findings using thismodel, however, these limitations
still exist. The novelty of the present study is that the exper-
iments can be appropriately controlled for vehicle, which al-
lows a more direct exploration of mechanism of action. It
could however be argued that this in itself is a limitation,
as metabolites may act differentially in serum relative in cell
culturemedia; Indeed, certain flavonoids have been shown to
interact with serum albumin in in vitro or ex vivo conditions
[25]. Furthermore, in utilizing average reported metabolite
concentrations, compositions do not reflect individual partic-
ipants’ blood profiles. Finally, the study design cannot cap-
ture the impact of other blood metabolites/analytes escaping
sample preparation and detection methodologies.
The highest mean concentration of metabolites detected
following the 500 mg bolus of 13C-labeled anthocyanins
(equivalent to the consumption of approximately 100 g of
blackberries [26]) was observed at 24 h post consumption and
totaled 4.38M[11]. In this study, a high inter-individual vari-
ation in metabolism was observed. For example, the serum
Cmax for hippuric acid was 1962 ± 1389 nM, indicating
the mean concentration varies greatly between individuals
and could be in excess of 3000 nM for a single metabo-
lite. The present study sought to address this issue by utiliz-
ing treatment concentrations reflecting the lowest and high-
est concentrations reported between individuals (0.80–13.18
M [8, 11]). As such, we used three metabolite concentra-
tions, representing 10-fold higher and lower concentrations
C© 2017 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 3. Effect of peakmetabo-
lite signatures on TNF- stimu-
lated IL-6 secretion by A) HU-
VEC, B) HCAEC. Cells were
treated with three concentra-
tions of three serum metabolite
profiles (representing ten-fold
lower and ten-fold higher con-
centrations than the mean con-
centrations observed by Czank
et al. [8]; Table 1) prior to the
addition of 10 or 0.1 ng/mL
TNF- for 24 h. Data were nor-
malized to a TNF- control (no
DMSO) and columns represent
the mean ± SD, n = 3 biolog-
ical replicates. Labeled means
without a common letter dif-
fer, p  0.05 (ANOVA with
post hoc LSD). *Different from
DMSO,p 0.05 (t-test). Abbrevi-
ations: HCAEC, human coronary
artery endothelial cells; TNF-,
tumor necrosis factor-; IL-6,
interleukin-6.
then the observed mean. Surprisingly, there was very little
difference in the inhibition of VCAM-1 protein expression
between the mean and ten-fold lower and higher concentra-
tions of the metabolites. This suggests that either there is
a threshold activity or that there is something unique about
these mixtures of metabolites which, when combined, have
some additive or synergistic activity. This outcome is impor-
tant as these concentrations reflect dietary achievable levels
[27]. As phenolic metabolites are common to a number of
dietary flavonoids and food sources [28], it is possible that
metabolite signature concentrations utilized in the present
study could be exceeded following a habitual polyphenol-rich
diet, given that consumption of polyphenols in Europe has
been estimated between 744–1786 mg/day [29]. As effects
were observed at the lowest concentrations in the present
study (between 0.19 and 0.44 M), even low levels of dietary
polyphenol consumption would have beneficial effects on in-
flammatory status.
Although peakmetabolite profiles inhibited IL-6 secretion
at 1, 6, and 24 h in HUVEC, this was not reflected in HCAEC,
though it is possible that effects were masked by the large
variation between replicates. It is possible that the reduced
stimulus (TNF-) concentration (0.1 ng/mL in the present
study relative to 10 ng/mL) increased variation as a result of
low IL-6 induction, making it difficult to quantify significant
activity.
The effects of the treatments on VCAM-1 and IL-6 mRNA
expression were investigated to determine whether these
C© 2017 The Authors. Molecular Nutrition & Food Research published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 4. Effect of peak metabolite signatures on TNF- stimu-
lated VCAM-1 and IL-6 mRNA expression in HCAEC (A) VCAM-
1, (B) IL-6. Cells were treated with the highest concentration
signature metabolites (19, 20, 44 M reflecting 1, 6, and 24 h
serum profiles respectively; Czank et al. [8]) and stimulated with
0.1 ng/mL TNF- for 4 h. Amplification values were normalized to
the geometric mean of two stable reference genes, VIPAS39 and
PRDM4. Data were normalized to a TNF- control (no DMSO) and
columns represent themean± SD, n = 3 biological replicates. La-
beledmeanswithout a common letter differ significantly, p 0.05
(ANOVA with post hoc LSD). *Different from DMSO, p  0.05
(t-test). Abbreviations: HCAEC, human coronary artery endothe-
lial cells; TNF-, tumor necrosis factor-; IL-6, interleukin-6;
VCAM-1, vascular adhesion molecule-1.
would reflect changes in protein expression. In our re-
cent study [5], it was observed that only protocatechuic acid
(PCA) inhibited VCAM-1 mRNA expression at the highest
tested concentration, 100 M. It is interesting that VCAM-
1 and IL-6 mRNAs were reduced by half in response to
the three metabolite profiles which reflect cumulative total
metabolite concentrations of only 19, 23, and 44 M, re-
spectively. Given the low concentrations of metabolites in
the present treatment mixtures, it appears that certain
metabolites are acting additively or synergistically, poten-
tially through effecting multiple pathways simultaneously.
Figure 5. Effect of peak metabolite signatures on TNF- stim-
ulated phosphor-NFB p65 expression in HCAEC. Cells were
treated with the highest concentration signature metabolites (19,
20, 44 reflecting 1, 6, and 24 h serum profiles respectively; Czank
et al. [8]), and stimulated with 10 ng/mL TNF- for 15 min. Data
were normalized to the vehicle control (DMSO) and columns rep-
resent the mean ± SD, n = 3 biological replicates. Blots are rep-
resentative of one of three replicates. Density values were nor-
malized to reference protein, GAPDH. Labeled means without a
common letter differ significantly, p 0.05 (ANOVAwith post hoc
LSD). Comparisons of untreated cells to vehicle control (DMSO)
were established via Student’s t-test, *p  0.05. Abbreviations:
HCAEC, human coronary artery endothelial cells; TNF-, tumor
necrosis factor-.
Multiple pathways are indeed thought to be affected follow-
ing anthocyanin metabolite treatment, for example, aortas
of ApoE-deficient mice fed an anthocyanin-rich bilberry ex-
tract, demonstrated themodulation of 1261 genes which code
for proteins involved in the regulation of cellular processes,
including adhesion and inflammatory biomarker expression
[14].
NFB is a key transcription factor pathway in the TNF-
stimulated expression of adhesion molecules in endothelial
cells [30]. In the present study, no effect was observed on
the expression of phosphorylated p65, suggesting alternative
mechanisms which influence adhesion molecule expression
are at play, such as AP-1 activity via p38 and JNKMAP kinase.
A recent study of ours [5] as well as that of Krga et al. [31] also
demonstrated no activity of flavonoid metabolites on NFB.
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Data from the present study suggest that the metabo-
lite profile with the maximum inflammatory effect was
observed at 24 h post-consumption, suggesting fasting or
chronic effects are possible. Conversely, improvements in
flow-mediated dilation (FMD) and blood pressure in response
to feeding anthocyanins are most often observed acutely, be-
tween 1 and 6 h post-consumption (maximum response at
2 h) [32]. In the study of Rodriguez-Mateos et al. [32], fol-
lowing the consumption of a drink containing blueberry an-
thocyanins, benzoic and vanillic acids positively correlated
with FMD at 1–2 h, whereas hippuric, hydroxyhippuric, and
homovanillic acids correlated with the FMD at 6 h. These
data suggests an acute-phase modulatory vascular response
of phenol metabolites. Based on these findings and those
of the present study it is possible that sudden vascular re-
sponses are mediated by very low levels of parent flavonoids
and their rapid degradation products, which are succeeded by
a delayed anti-inflammatory response, mediated by products
of lower intestinal bacterial catabolism and hepatic phase II
conjugation. This ultimately suggests a dual mechanistic ac-
tivity of flavonoids. This hypothesis requires conformation in
randomized-control trials designed having inflammation as a
primary endpoint and utilizing populations both responsive
to inflammatory and vascular intervention following dietary
manipulation (i.e., neither completely healthy nor chronically
unhealthy), as flavonoids are likely to be effective as a preven-
tative strategy rather than a pharmacological therapy.
In conclusion, the present study identified that signatures
of anthocyanin metabolites, identified post consumption of
dietary achievable levels of anthocyanins, have inhibitory ef-
fects on inflammatory protein secretion. Further work is re-
quired to elucidate the multiple mechanisms potentially at
play, ultimately informing our understanding of how antho-
cyanins and other flavonoids impact health.
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